DE69034076D1 - Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie - Google Patents

Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie

Info

Publication number
DE69034076D1
DE69034076D1 DE69034076T DE69034076T DE69034076D1 DE 69034076 D1 DE69034076 D1 DE 69034076D1 DE 69034076 T DE69034076 T DE 69034076T DE 69034076 T DE69034076 T DE 69034076T DE 69034076 D1 DE69034076 D1 DE 69034076D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
myeloid leukemia
manufacture
treatment
chronic myeloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69034076T
Other languages
English (en)
Other versions
DE69034076T2 (de
Inventor
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Interpharm Laboratories Ltd filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of DE69034076D1 publication Critical patent/DE69034076D1/de
Publication of DE69034076T2 publication Critical patent/DE69034076T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69034076T 1989-03-19 1990-03-15 Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie Expired - Lifetime DE69034076T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL89662A IL89662A (en) 1989-03-19 1989-03-19 Pharmaceutical compositions comprising interferon-beta

Publications (2)

Publication Number Publication Date
DE69034076D1 true DE69034076D1 (de) 2003-06-18
DE69034076T2 DE69034076T2 (de) 2003-11-20

Family

ID=11059803

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69031355T Expired - Lifetime DE69031355T2 (de) 1989-03-19 1990-03-15 Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis
DE69034076T Expired - Lifetime DE69034076T2 (de) 1989-03-19 1990-03-15 Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69031355T Expired - Lifetime DE69031355T2 (de) 1989-03-19 1990-03-15 Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis

Country Status (12)

Country Link
US (1) US5104653A (de)
EP (2) EP0643973B1 (de)
JP (1) JP2883669B2 (de)
AT (2) ATE240116T1 (de)
AU (1) AU619960B2 (de)
CA (1) CA2011992C (de)
DE (2) DE69031355T2 (de)
DK (2) DK0643973T3 (de)
ES (2) ES2198409T3 (de)
GR (1) GR3024763T3 (de)
IL (1) IL89662A (de)
ZA (1) ZA901994B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
DE69636790T2 (de) * 1995-07-25 2007-10-11 Toray Industries, Inc. Interferon-beta gegen knochenerkrankungen
JP2002509077A (ja) * 1998-02-09 2002-03-26 ユニヴァースティ オブ サザーン カリフォルニア 赤血球形成促進方法
DE60139339D1 (de) * 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
EP1334177B1 (de) * 2000-11-14 2005-01-26 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8084424B2 (en) * 2003-04-09 2011-12-27 University Of Utah Research Foundation Compositions and methods related to erythropoietin
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
CA2561141A1 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
CA1294215C (en) * 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4851219A (en) * 1986-11-18 1989-07-25 Genentech, Inc. Method for the treatment of chronic myelogenous leukemia
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
IL89662A0 (en) 1989-09-28
EP0643973A1 (de) 1995-03-22
CA2011992A1 (en) 1990-09-19
DE69031355D1 (de) 1997-10-09
ATE240116T1 (de) 2003-05-15
DE69034076T2 (de) 2003-11-20
IL89662A (en) 1997-11-20
ES2198409T3 (es) 2004-02-01
GR3024763T3 (en) 1997-12-31
US5104653A (en) 1992-04-14
DE69031355T2 (de) 1998-01-08
EP0388799A3 (de) 1991-07-31
AU5144590A (en) 1990-09-20
JPH0314523A (ja) 1991-01-23
JP2883669B2 (ja) 1999-04-19
EP0388799A2 (de) 1990-09-26
DK0388799T3 (da) 1998-03-30
DK0643973T3 (da) 2003-09-08
ZA901994B (en) 1990-12-28
ATE157544T1 (de) 1997-09-15
ES2107414T3 (es) 1997-12-01
EP0388799B1 (de) 1997-09-03
CA2011992C (en) 2003-04-29
EP0643973B1 (de) 2003-05-14
AU619960B2 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
ATE135363T1 (de) Nucleoside zur verwendung für die therapie
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DE59000270D1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
ZA848369B (en) Pharmaceutical compositions containing bilobalid for the treatment of neuropathies
DE69034076D1 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
UA45942A (uk) 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
GR3025488T3 (en) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE80039T1 (de) Pharmazeutische zusammensetzung, enthaltend 2',3'-dideoxycytidin-2'-en(2',3'-dideoxy-2',3'didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE247474T1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
NO873934D0 (no) Fremgangsmaate for forbedret saarheling.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ATE130194T1 (de) Subkutane verabreichung des humanen choriongonadotropins.
ATE70444T1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
GR3004272T3 (de)
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
ATE76571T1 (de) Zusammensetzung zur behandlung der haut.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition